Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
about
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.Bone Metastases: An Overview.Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.Accelerated bone mass senescence after hematopoietic stem cell transplantation.Myeloma and Bone Disease.Bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva)
P2860
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@ast
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@en
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@nl
type
label
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@ast
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@en
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@nl
prefLabel
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@ast
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@en
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@nl
P2860
P921
P356
P1476
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
@en
P2860
P356
10.2147/CIA.S14566
P407
P577
2012-01-01T00:00:00Z
2012-09-03T00:00:00Z